Evommune, Inc. (EVMN)

Evommune is a clinical-stage biotechnology company developing therapies that target key drivers of chronic immune-mediated inflammation. Early clinical programs address chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis with candidates such as EVO756 and EVO301. The focus is on improving day-to-day disease control and reducing long-term damage from uncontrolled inflammation where existing options fall short.

Market
NYSE
Sector
Healthcare
Trend
Neutral
Last close
7.24 (+5.23% on the day)
MA50
7.2
MA200
16.92
52-week range
5.1–31.57
Market cap
299.4M USD
Dividend yield
0%
Data as of
2026-11-19
Quarterly revenue and earnings, millions of USD
QuarterRevenueYoY %EarningsYoY %
Q4 20240—-22.2—
Q3 202510—-12.5—
Q4 20250—-28.3—
Q1 20260—-21.7—
Q2 20260—-32.3—

All markets — KeepWinning global stock screener

Other companies on NYSE: Apollo Commercial Real Estate Finance, Inc. (ARI), Regional Management Corp. (RM), BlackRock Floating Rate Income Trust (BGT), Alpine Income Property Trust, Inc. (PINE), CH4 Natural Solutions Corporation (MTNE), KPET Ultra Paceline Corporation (KPET)